Lys479
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys479  -  MCT1 (human)

Site Information
GkPNEVTkAAEsPDQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12332173

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:
lung cancer ( 3 ) , non-small cell lung adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:
293T (epithelial) ( 5 ) , A549 (pulmonary) ( 3 ) , HEp-2 (squamous) ( 1 ) , JJN3 (plasma cell) ( 8 ) , Jurkat (T lymphocyte) ( 1 ) , MV4-11 (macrophage) ( 5 ) , U266 (plasma cell) ( 7 )

Upstream Regulation
Treatments:
vorinostat ( 3 )

References 

1

Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640
29967540   Curated Info

2

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

3

Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284   Curated Info

4

Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983   Curated Info

5

Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284
21890473   Curated Info

6

Guo A (2009) CST Curation Set: 8657; Year: 2009; Biosample/Treatment: cell line, KMS-12-BM/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

7

Guo A (2009) CST Curation Set: 8643; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

8

Guo A (2009) CST Curation Set: 8648; Year: 2009; Biosample/Treatment: cell line, JJN3/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

9

Guo A (2009) CST Curation Set: 8640; Year: 2009; Biosample/Treatment: cell line, L363/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info